SCHEMBL23328706

SCHEMBL23328706

COc1cc(OC)cc(-c2cc3cnc(SC)nc3nc2Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.50
FGFR4 P22455 6/20 0.39
FGFR2 P21802 3/20 0.39
FGFR3 P22607 3/20 0.39
EGFR P00533 1/20 0.39
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KDR P35968 2/20 0.36
AURKA O14965 1/20 0.36
AURKB Q96GD4 1/20 0.36
FLT1 P17948 1/20 0.36
FLT4 P35916 1/20 0.36
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
AKT1 P31749 1/20 0.34
AKT2 P31751 1/20 0.34
CYP1A1 P04798 1/20 0.34
CYP1B1 Q16678 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31648203 0.84 FGFR1 (0.71) FGFR1FGFR4FGFR2FGFR3EGFR
SCHEMBL16072038 0.84 FGFR1 (0.71) FGFR1FGFR4FGFR2FGFR3EGFR
SCHEMBL21783951 0.83 MEN1 (0.36) FGFR1FGFR4FGFR2KDR
SCHEMBL23328708 0.81 FGFR1 (0.50) FGFR1FGFR4FGFR2FGFR3EGFR
SCHEMBL2893422 0.80 AKT1 (0.48) AKT1AKT2
SCHEMBL21761868 0.78 FGFR4 (0.36) FGFR1FGFR4KDRAURKAAURKB
SCHEMBL29546429 0.78 CYP1A1 (0.45) FGFR1FGFR4NPC1RAB9ACYP1A1
SCHEMBL30450919 0.76 NPC1 (0.46) FGFR1FGFR4NPC1RAB9ACYP1A1
SCHEMBL20331427 0.76 NPC1 (0.46) FGFR1FGFR4NPC1RAB9ACYP1A1
SCHEMBL19817005 0.75 FGFR1 (0.39) FGFR1KDRAURKAAURKBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365196-B2 FGFR inhibitor and application thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2022-06-21 US disclosed
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365196-B2 FGFR inhibitor and application thereof FGFR1, FGFR4, FGFR2 FGFR1 1/4885FGFR4 2/4885FGFR2 3/4885
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF FGFR1, FGFR4, FGFR2 FGFR1 1/4885FGFR4 2/4885FGFR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.